Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating two different pacing methods for patients with slow heart rates, called bradycardia. This study compares the common right ventricular pacing approach with a newer physiological pacing method that includes His bundle and left bundle area pacing. The trial aims to better understand how these pacing techniques affect patient outcomes, including mortality and heart failure morbidity, in a large group of 2600 patients. Participants will receive a pacemaker implant and be randomly assigned to either right ventricular pacing or physiological pacing. The physiological pacing may involve His bundle pacing or left bundle pacing, but if these are not successful, biventricular pacing will be used. A subgroup of 500 participants will take part in an optional echocardiographic sub-study to assess heart function changes over a 24-month period. Throughout the study, patients will be assessed at baseline and every six months after randomization, with follow-up lasting up to 78 months. Researchers will monitor outcomes such as mortality, heart failure events, device-related safety issues, patient quality of life, symptoms, and pacemaker-derived data like arrhythmias and activity levels. The echocardiographic sub-study will measure specific heart function changes to understand pacing-induced cardiomyopathy. Participants involvement includes implantation, regular follow-up visits, questionnaires, and optional imaging assessments.
Actively Recruiting
Researchers are evaluating whether skipping additional axillary treatment for patients with early-stage breast cancer who had cancer in their lymph nodes before chemotherapy but show no remaining cancer in those nodes after treatment is as effective as the standard approach. This study focuses on disease-free survival and reducing the risk of lymphoedema five years after treatment. It is a randomized, open, multicenter trial including patients with specific breast cancer stages and confirmed nodal metastases. Participants will all receive standard therapies including HER2-targeted treatment, endocrine therapy, and radiotherapy to the breast or chest wall if needed. They will be randomly assigned to one of two groups one group will not get further axillary treatment such as lymph node removal or radiotherapy, while the other group will receive these axillary treatments according to local guidelines. Follow-up visits will occur annually for at least five years. During the study, participants will undergo assessments to monitor disease-free survival and self-reported lymphoedema using specific questionnaires. Additional evaluations include arm function, quality of life, recurrence rates, survival, and cost-effectiveness analyses. The total study duration is planned for 120 months, including setup, recruitment, follow-up, analysis, and reporting.
Actively Recruiting
This research is investigating the use of Implantable Cardioverter-Defibrillators ICDs in adults diagnosed with heart failure caused by Non-Ischemic Cardiomyopathy NICM, a condition where heart failure is not due to blocked arteries. The study aims to compare the all-cause mortality rates between patients who receive an ICD and those who do not, over a period of 36 months and extending up to 10 years. This trial addresses ongoing questions about whether ICDs benefit patients with NICM, especially given recent findings that many patients with ICDs do not experience serious heart rhythm problems. Participants are randomly assigned to one of two groups one group will have an ICD or Cardiac Resynchronisation Therapy Defibrillator CRTD implanted, which are devices designed to detect and correct dangerous heart rhythms. The other group will not receive an ICD but may have an Implantable Loop Recorder or a Cardiac Resynchronisation Therapy Pacemaker CRTP, alongside their usual medical care. The study will monitor both groups to determine if ICD implantation improves survival compared to no ICD over the study period. Throughout the trial, participants will be regularly evaluated with health assessments including quality of life questionnaires and monitoring of heart-related events such as hospitalizations and arrhythmias. Researchers will track outcomes like survival percentage, heart rhythm events, and device-related procedures over 3 years, with some outcomes also measured at 5 and 10 years. The study includes close observation of safety and effectiveness, with participants followed to understand long-term impacts of ICD therapy in this patient group.
Actively Recruiting
Researchers are evaluating the real-world use of nemolizumab for treating moderate-to-severe atopic dermatitis AD in adolescents and adults. This observational study aims to assess the treatments effectiveness through physician evaluations and patient-reported outcomes over six months, providing insight into how the medication performs in everyday clinical practice. Participants receiving nemolizumab as part of their routine care will be observed for about 12 months. Treatment decisions are made by the participants physician before joining the study, with no extra visits or tests beyond usual medical care. A sub-study in Germany and the UK involves daily remote reporting of symptoms such as peak and average itch, sleep disturbance, and pain for the first two weeks. During the study, participants will have regular medical visits as determined by their doctors, with data collected from routine assessments and patient questionnaires. Researchers will measure outcomes like the Investigator Global Assessment and Peak Pruritus Numerical Rating Scale at six months, along with other severity and symptom scores up to 12 months. No additional procedures outside standard care are required, allowing for natural monitoring of treatment effects and safety.
Actively Recruiting
This research is a rollover study for participants who have previously taken part in specific Incyte-sponsored clinical trials involving the drug povorcitinib, aimed at treating Hidradenitis Suppurativa HS. The purpose is to continue evaluating the treatments safety and tolerability over an extended period, building on prior studies. Participants must have completed treatment in the original trials without major safety concerns and shown clinical benefits. Participants will continue to receive povorcitinib orally, following the same dosing schedule and options as in their original parent study. This ongoing treatment phase allows researchers to monitor long-term effects and gather extended safety data. The study is designed as a single-group phase 3b trial focused on treatment. Throughout the study, participants will be regularly monitored for treatment-emergent adverse events over approximately three years. Researchers will also assess specific clinical measures at each visit to evaluate treatment impact. Participants are expected to comply with study procedures, including avoiding pregnancy or fathering children as outlined. The total participation duration extends up to about three years, with regular visits to track safety and treatment outcomes.
Actively Recruiting
This research aims to evaluate two types of ostomy seals or rings in patients who have recently undergone ostomy surgery. It focuses on preventing and managing complications related to the skin around the stoma, known as peristomal skin complications PSCs. The study is sponsored by Hollister Incorporated and involves post-operative patients with colostomy, ileostomy, or urostomy, assessing how these devices perform in real-world use. Participants will be randomly assigned to use either an absorptive ostomy seal or an ostomy ring containing Aloe. These devices are applied at the first pouch change following surgery or up to four days after the operation. The study treatment period lasts for nine weeks, during which patients use the assigned seal or ring as part of their ostomy care. The trial compares the two devices to monitor skin complications and other related outcomes. During the study, participants will be followed from enrollment through the nine-week treatment phase with regular assessments. Researchers will track skin complications using the Ostomy Complication Severity Index OCSI, including measures of leakage, moisture, skin conditions, and patient and clinician satisfaction. The study also collects data on usage patterns, healthcare visits related to the ostomy, and costs associated with the seals or rings. The overall goal is to understand the devices impact on skin health and patient experience after ostomy surgery.
Actively Recruiting
Researchers are conducting a prospective, observational study to assess the health of multiple organs in adults with type 2 diabetes who have no history of cardiovascular disease. The goal is to understand if detailed MRI measurements can help predict future clinical events over a 5-year period. Participants include adults diagnosed with type 2 diabetes, especially those diagnosed within the last three years. Participants will undergo no changes to their standard medical care. The study involves two main visits within one month the first includes body measurements and collection of blood and urine samples for routine diabetes checks, and the second involves a multi-organ, multiparametric MRI scan. Data from these visits, along with access to medical records, will be used to monitor disease progression and predict outcomes over 1, 3, and 5 years. Throughout the 5-year study, researchers will collect MRI metrics, clinical outcomes, and lab samples to evaluate diabetes progression. Participants consent to access their hospital and mortality records for event tracking. The primary outcome is the rate of major cardiovascular events three years after the baseline MRI. Secondary outcomes include kidney, eye, liver, cancer, and mortality events assessed at 1, 3, and 5 years. The study requires only a short period of active participation, with long-term follow-up through record review.
Actively Recruiting
Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.